Objectives: Understand the main features of the disease, the challenges with the treatments and how to choose between antibiotics and biotherapies.
Introduction: As HS is both an infectious and auto-inflammatory disease, treatments can be both antibiotics and anti-cytokines antibodies, mainly anti-TNF-alpha. Surgery is also an important option which will be discussed in another session.
Materials / method: Review of the literature ans experience of RESOVERNEUIL in France (french network for HS).
Results: The main protocol is the association of rifampicin / clindamycin. Many protocols have derived now from this historical one: rifampicin / ofloxacin; rifampicin / moxifloxacin / metronidazole in induction phase, and then cotrimoxazole in maintenance phase. For biologics, the anti-TNF adalumimab in the only one to have an agreement in Europe. But many new molecules are under investigation: anti-IL-17 (secukinumab), anti-IL-23 (guselkumab), anti-complement fractions (anti-C5a). The field of treatments is now increasing every year.
Conclusion: The best option depends on the main clinical presentation: purulent or rather inflammatory phase. In a same patient, treatment can change depending on a particular phase of the disease. It remains anyway a multidisciplinary approach.
Declaraciones
¿Ha recibido algún tipo de financiamiento para realizar su investigación sobre esta temática?
No
¿Ha recibido algún pago, honorario u otra compensación por su trabajo acerca de esta investigación?
No
¿Tiene vínculos financieros con alguna entidad que podría llegar a competir estrechamente con los medicamentos, materiales o instrumentos tratados en su investigación?
No
¿Posee o ha solicitado una patente relacionada a los materiales, productos o instrumentos utilizados en su investigación?
No
Este trabajo no cuenta con el apoyo de ningún financiamiento directo o indirecto. El autor asume plena responsabilidad sobre el mismo.